Signal Transduction and Targeted Therapy最新文献

{"title":"Subnanomolar MAS-related G protein-coupled receptor-X2/B2 antagonists with efficacy in human mast cells and disease models","authors":"Ghazl Al Hamwi, Mohamad Wessam Alnouri, Sven Verdonck, Piotr Leonczak, Shaswati Chaki, Stefan Frischbutter, Pavel Kolkhir, Michaela Matthey, Constantin Kopp, Marek Bednarski, Yvonne K. Riedel, Daniel Marx, Sophie Clemens, Vigneshwaran Namasivayam, Susanne Gattner, Dominik Thimm, Katharina Sylvester, Katharina Wolf, Andreas E. Kremer, Steven De Jonghe, Daniela Wenzel, Magdalena Kotańska, Hydar Ali, Piet Herdewijn, Christa E. Müller","doi":"10.1038/s41392-025-02209-8","DOIUrl":"https://doi.org/10.1038/s41392-025-02209-8","url":null,"abstract":"<p>The MAS-related G protein-coupled receptor-X2 (MRGPRX2), an orphan receptor expressed on mast cells (MCs), is upregulated upon inflammation and induces hypersensitivity and inflammatory diseases. In contrast to the large number of MRGPRX2 agonists, only a few antagonists have been described, and no optimization has been reported to improve potency, selectivity, and drug-like properties. Antagonists with ancillary inhibition of the putative mouse ortholog MRGPRB2 have not been described. Here, we present a multi-disciplinary approach involving chemistry, biology, and computational science, resulting in the development of a small-molecule MRGPRX2 antagonist (PSB-172656, 3-ethyl-7,8-difluoro-2-isopropylbenzo[4,5]imidazo [1,2-<i>a</i>] pyrimidin-4(1<i>H</i>)-one) based on a fragment screening hit. The compound exhibits metabolic stability, low cytotoxicity, and competitive blockade of MRGPRX2 activation induced by a diverse range of agonists. It displays subnanomolar potency in Ca²⁺ mobilization assays (<i>K</i>_i value 0.142 nM) and was found to block MRGPRX2-mediated Gα_q and Gα_i1 dissociation, in addition to <i>β</i>-arrestin-2 recruitment. PSB-172656 is selective for MRGPRX2 versus all other MRGPRX subtypes. Its effect on MCs was confirmed in cell lines, including rat basophilic leukemia cells (RBL-2H3) recombinantly expressing human MRGPRX2, human Laboratory of Allergic Diseases 2 (LAD2) MCs, and native human skin MCs. PSB-172656 was found to additionally block the putative mouse ortholog of MRGPRX2, MRGPRB2, as determined in Ca²⁺ mobilization assays (<i>K</i>_i 0.302 nM), and to prevent mouse tracheal contractions, local allergic reactions, and systemic anaphylactic symptoms. PSB-172656 constitutes a unique pharmacological tool and has the potential to be developed as a drug for mast cell-mediated hypersensitivity reactions and chronic inflammatory diseases, addressing a huge unmet medical need.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"29 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-27: overclocking cytotoxic T lymphocytes to boost cancer immunotherapy","authors":"Silvia Dusi, Vincenzo Bronte, Francesco De Sanctis","doi":"10.1038/s41392-025-02212-z","DOIUrl":"https://doi.org/10.1038/s41392-025-02212-z","url":null,"abstract":"<p>In a recent study published in <i>Nature</i>, Breart et al.¹ untangled the controversy surrounding interleukin (IL)-27’s role in regulating T cell differentiation and immune responses in cancer. Their findings reveal that IL-27 enhances the persistence and effector functions of tumor-infiltrating CD8⁺ T lymphocytes (TILs), preventing exhaustion, sustaining T cell-dependent tumor control and immunotherapy efficacy without significant systemic side effects.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"255 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conversion of Ku80 K568 crotonylation to SUMOylation facilitates DNA non-homologous end joining and cancer radioresistance","authors":"Hongling Zhao, Shanshan Gao, Yang Han, Dafei Xie, Lihui Xuan, Xin Huang, Jinhua Luo, Qian Ran, Gang Li, Hejiang Guo, Weixiang Hu, Jin Jia, Xiaochang Liu, Yuhao Liu, Jinpeng Tan, Chenjun Bai, Yongqing Gu, Teng Ma, Zhongjun Li, Hua Guan, Ruixue Huang, Ping-Kun Zhou","doi":"10.1038/s41392-025-02210-1","DOIUrl":"https://doi.org/10.1038/s41392-025-02210-1","url":null,"abstract":"<p>Chemo-/radioresistance of malignant tumors hampers cancer control and increases patient mortality. Efficient repair of damaged DNA is critical for the maintenance of genomic integrity and fidelity of genetic information. In reverse, increased DNA repair capability in cancer cells contributes to chemo-/radioresistance of malignant tumors. DNA double-strand break (DSB) is the most serious DNA damage and is also the principal molecular basis of radiotherapy. Upon DNA damage, the Ku80 is recruited and forms a critical DNA-PK complex at the DSB sites with Ku70 and the catalytic subunit (DNA-PKcs) to initiate DNA repair. How DNA-PK is assembled and activated is not fully understood. Based on the identification of radiation-reduced Ku80 K568 crotonylation through quantitative global lysine crotonylome analysis, we reveal that Ku80 K568 is crotonylated by p300-CBP-associated factor (PCAF). Upon DNA damage, the K568cr is decrotonylated by HDAC8 (Histone deacetylase 8). Decrotonylation of K568cr empties this site for the subsequent SUMOylation of Ku80 by CBX4. The conversion of Ku80 from K568 crotonylation to SUMOylation facilitates the assembly of DNA-PK complex and autophosphorylation of DNA-PKcs S2056, consequently activating the DSB repair. Moreover, mutation disrupting the post-translational modification (PTM) of Ku80 K568 site sensitizes cancer cells to radiotherapy in tumor-bearing nude mice models. This study elucidates the conversion model between two different forms of PTMs in the regulation of DNA-PK complex assembly and DSB repair, highlighting this model’s potential in controlling chemo-/radioresistance of malignant tumors, as well as expands the atlas of therapeutic targets.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"45 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143853096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNase1-driven ALK-activation is an oncogenic driver and therapeutic target in non-small cell lung cancer","authors":"Zhengyu Zha, Chunxiao Liu, Meisi Yan, Cong Chen, Cheng Yu, Yaohui Chen, Chenhao Zhou, Lu Li, Yi-Chuan Li, Hiro Yamaguchi, Leiguang Ye, Tong Liu, Ying-Nai Wang, Heng-Huan Lee, Wen-Hao Yang, Li-Chuan Chan, Baozhen Ke, Jennifer L. Hsu, Lieming Ding, Dong Ji, Peng Pan, Yiran Meng, Yue Pu, Lunxu Liu, Mien-Chie Hung","doi":"10.1038/s41392-025-02206-x","DOIUrl":"https://doi.org/10.1038/s41392-025-02206-x","url":null,"abstract":"<p>Targeted therapy has achieved significant success in the treatment of non-small cell lung cancer (NSCLC), particularly in patients harboring common oncogenic driver mutations such as EGFR, KRAS, and ALK rearrangement. However, ~35–50% of NSCLC patients without tyrosine kinase mutation or rearrangement (non-mutated) cannot benefit from these targeted treatments, highlighting the urgent need for novel therapeutic strategies for this patient population. In this study, we report a non-canonical role of human secretory ribonuclease 1 (RNase1), which binds to and activates wild-type ALK in lung cancer cells, thereby triggering its downstream signaling pathway. RNase1-driven ALK-activation (RDAA) cells exhibit enhanced cell proliferation, migration, and colony formation. Additionally, RDAA facilitates tumor formation in fibroblast models, further underscoring its oncogenic potential in vivo. Importantly, RDAA lung cancer cells exhibit marked sensitivity to FDA-approved ALK inhibitors. Tumor growth suppression and survival were substantially improved in both RDAA-positive NSCLC cell line-derived and patient-derived xenograft tumor models treated with ALK inhibitors. Monoclonal antibodies against RNase1 and phosphorylated-ALK were used to analyze two different human NSCLC tissue cohorts by immunohistochemical staining identified 10.4% (5/48) and 8.5% (100/1173) patients who were RDAA positive, respectively. Notably, among the nine RDAA-positive NSCLC patients who accepted ALK inhibitor treatment, five achieved objective response including two who experienced complete response (CR). Together, the current study identifies RDAA as an oncogenic driver and proposes an effective targeted therapy strategy for non-mutated NSCLC patients.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"122 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer chemoprevention: signaling pathways and strategic approaches","authors":"Junling Ren, Guangli Yan, Le Yang, Ling Kong, Yu Guan, Hui Sun, Chang Liu, Lei Liu, Ying Han, Xijun Wang","doi":"10.1038/s41392-025-02167-1","DOIUrl":"https://doi.org/10.1038/s41392-025-02167-1","url":null,"abstract":"<p>Although cancer chemopreventive agents have been confirmed to effectively protect high-risk populations from cancer invasion or recurrence, only over ten drugs have been approved by the U.S. Food and Drug Administration. Therefore, screening potent cancer chemopreventive agents is crucial to reduce the constantly increasing incidence and mortality rate of cancer. Considering the lengthy prevention process, an ideal chemopreventive agent should be nontoxic, inexpensive, and oral. Natural compounds have become a natural treasure reservoir for cancer chemoprevention because of their superior ease of availability, cost-effectiveness, and safety. The benefits of natural compounds as chemopreventive agents in cancer prevention have been confirmed in various studies. In light of this, the present review is intended to fully delineate the entire scope of cancer chemoprevention, and primarily focuses on various aspects of cancer chemoprevention based on natural compounds, specifically focusing on the mechanism of action of natural compounds in cancer prevention, and discussing in detail how they exert cancer prevention effects by affecting classical signaling pathways, immune checkpoints, and gut microbiome. We also introduce novel cancer chemoprevention strategies and summarize the role of natural compounds in improving chemotherapy regimens. Furthermore, we describe strategies for discovering anticancer compounds with low abundance and high activity, revealing the broad prospects of natural compounds in drug discovery for cancer chemoprevention. Moreover, we associate cancer chemoprevention with precision medicine, and discuss the challenges encountered in cancer chemoprevention. Finally, we emphasize the transformative potential of natural compounds in advancing the field of cancer chemoprevention and their ability to introduce more effective and less toxic preventive options for oncology.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"8 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like","authors":"Rou Li, Lin Liu, Min Wu","doi":"10.1038/s41392-025-02211-0","DOIUrl":"https://doi.org/10.1038/s41392-025-02211-0","url":null,"abstract":"<p>A study by Wei et al. in <i>Science</i> identified a unique sexual binary neural circuit encoding a sexual preference switch, known as the ventral tegmental area dopaminergic (VTA^DA) circuit, which exhibits a preference for female social interactions among both sex mice, but switches to male preferences when confronted with survival threats (Fig. 1).¹</p><figure><figcaption><b data-test=\"figure-caption-text\">Fig. 1</b></figcaption><picture><source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-025-02211-0/MediaObjects/41392_2025_2211_Fig1_HTML.png?as=webp\" type=\"image/webp\"/><img alt=\"figure 1\" aria-describedby=\"Fig1\" height=\"816\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41392-025-02211-0/MediaObjects/41392_2025_2211_Fig1_HTML.png\" width=\"685\"/></picture><p><b>a</b> Schematic diagram illustrating the social preference test. Both male and female mice exhibited a preference for social interaction with females. However, this preference shifted to male preference when facing survival threats (TMT, contextual FC, or cued FC). <b>b</b> The sexually dimorphic DA circuits involve the sociosexual preferences of females and males. C-Fos staining revealed that the activity changes in VTA^DA and their downstream circuits, the mPOA and the NAc, are closely related to these changes. A calcium signaling fiber optic recording method for real-time monitoring of VTA^DA neural activity during social processes, along with a chemical genetics approach for activating VTA^DA neurons. Dual-color calcium signal fiber recording combined with viral tracing for synchronous monitoring of VTADA neuronal subpopulation activity. Chemical genetic methods were employed to manipulate the VTA^DA-mPOA and VTA^DA-NAc projection. The competitive balance between VTA^DA-NAc and the defense loop VTA^DA-mPOA determines the social preferences of male animals. By employing optogenetic techniques, the VTA-NAc projection was stimulated with light in both tonic and phasic discharge modes. Female individuals selectively regulate downstream neurons by modulating firing patterns in the VTA^DA-NAC) ultimately shaping their social preferences. TMT trimethylthiazoline, FC fear conditioning, VTA ventral tegmental area, mPOA midbrain preoptic area, NAc nucleus accumbens, CNO clozapine N-oxide, D1R type 1 DA receptor, D2R type 2 DA receptor. This figure was created with BioRender.com</p><span>Full size image</span><svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></figure>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"6 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143846500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep insight into cytokine storm: from pathogenesis to treatment","authors":"Jiali Nie, Ling Zhou, Weiwei Tian, Xiansheng Liu, Liping Yang, Xingcheng Yang, Yicheng Zhang, Shuang Wei, Dao Wen Wang, Jia Wei","doi":"10.1038/s41392-025-02178-y","DOIUrl":"https://doi.org/10.1038/s41392-025-02178-y","url":null,"abstract":"<p>Cytokine storm (CS) is a severe systemic inflammatory syndrome characterized by the excessive activation of immune cells and a significant increase in circulating levels of cytokines. This pathological process is implicated in the development of life-threatening conditions such as fulminant myocarditis (FM), acute respiratory distress syndrome (ARDS), primary or secondary hemophagocytic lymphohistiocytosis (HLH), cytokine release syndrome (CRS) associated with chimeric antigen receptor-modified T (CAR-T) therapy, and grade III to IV acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. The significant involvement of the JAK-STAT pathway, Toll-like receptors, neutrophil extracellular traps, NLRP3 inflammasome, and other signaling pathways has been recognized in the pathogenesis of CS. Therapies targeting these pathways have been developed or are currently being investigated. While novel drugs have demonstrated promising therapeutic efficacy in mitigating CS, the overall mortality rate of CS resulting from underlying diseases remains high. In the clinical setting, the management of CS typically necessitates a multidisciplinary team strategy encompassing the removal of abnormal inflammatory or immune system activation, the preservation of vital organ function, the treatment of the underlying disease, and the provision of life supportive therapy. This review provides a comprehensive overview of the key signaling pathways and associated cytokines implicated in CS, elucidates the impact of dysregulated immune cell activation, and delineates the resultant organ injury associated with CS. In addition, we offer insights and current literature on the management of CS in cases of FM, ARDS, systemic inflammatory response syndrome, treatment-induced CRS, HLH, and other related conditions.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"108 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143836678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial","authors":"Huijie Bian, Liang Chen, Zheng Zhang, Ai-Dong Wen, Zhao-Hui Zheng, Li-Qiang Song, Meng-Ying Yao, Ying-Xia Liu, Xi-Jing Zhang, Hong-Lin Dong, Jian-Qi Lian, Lei Pan, Yu Liu, Xing Gu, Hui Zhao, Jing-Wen Wang, Qing-Yi Wang, Kui Zhang, Jun-Feng Jia, Rong-Hua Xie, Xing Luo, Xiang-Hui Fu, Yan-Yan Jia, Jun-Na Hou, Qiu-Yue Tan, Xiao-Xia Chen, Liu-Qing Yang, Yuan-Long Lin, Xiao-Xia Wang, Lei Zhang, Qin-Jing Zeng, Wen-Jie Li, Rui-Xuan Wang, Yang Zhang, Xiu-Xuan Sun, Bin Wang, Xu Yang, Jian-Li Jiang, Ling Li, Jiao Wu, Xiang-Min Yang, Hai Zhang, Ying Shi, Xiao-Chun Chen, Hao Tang, Hong-Wei Shi, Shuang-Shuang Liu, Yong Yang, Tian-Yi Yang, Ding Wei, Zhi-Nan Chen, Ping Zhu","doi":"10.1038/s41392-025-02208-9","DOIUrl":"https://doi.org/10.1038/s41392-025-02208-9","url":null,"abstract":"<p>Meplazumab, a humanized CD147 antibody, showed favorable safety and clinical benefits in phase 1 and phase 2/3 seamless clinical studies. Further evaluation of its therapeutic efficacy in patients with severe COVID-19 is needed. In this phase 3 add-on study, we randomized patients with severe COVID-19 in a 1:1 ratio to receive 0.2 mg/kg meplazumab or placebo via intravenous injection, and evaluated efficacy and safety within 56 days. Between February 2023 and November 2023, 108 patients with severe COVID-19 were randomized to two groups, with their baseline characteristics generally balanced. The primary endpoint, 28-day all-cause mortality was 1.96% in the meplazumab group vs 7.69% in the placebo group (<i>P</i> = 0.1703). Supplementary analysis using composite strategy indicated a significant reduction of 28-day all-cause mortality in meplazumab compared to placebo (3.92% vs 15.38%, <i>P</i> = 0.044). Meplazumab also significantly reduced the mortality in smoking subjects on day 28 (<i>P</i> = 0.047) compared to placebo in supplementary analysis. The secondary endpoint, 56-day all-cause mortality, was 1.96% in the meplazumab group and 11.54% in the placebo group (<i>P</i> = 0.048), which was 3.92% and 15.38%, respectively (<i>P</i> = 0.044) by supplementary analysis. Additional secondary endpoints showed potential benefits, including increased hospital discharge rates, improved clinical outcomes, and improved viral nucleotide conversion rate. Meplazumab demonstrated good safety and tolerability, with no grade ≥ 3 TEAEs observed. These promising results indicate that meplazumab reduces mortality and enhances clinical benefits in severe COVID-19 patients with a good safety profile, providing effective and specific therapeutics for severe COVID-19 (the trial was registered at ClinicalTrials.gov (NCT05679479)).</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"6 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncogenic gene fusions in cancer: from biology to therapy","authors":"Stephen V. Liu, Misako Nagasaka, Judith Atz, Flavio Solca, Leonhard Müllauer","doi":"10.1038/s41392-025-02161-7","DOIUrl":"https://doi.org/10.1038/s41392-025-02161-7","url":null,"abstract":"<p>Oncogenic gene fusions occur across a broad range of cancers and are a defining feature of some cancer types. Cancers driven by gene fusion products tend to respond well to targeted therapies, where available; thus, detection of potentially targetable oncogenic fusions is necessary to select optimal treatment. Detection methods include non-sequencing methods, such as fluorescence in situ hybridization and immunohistochemistry, and sequencing methods, such as DNA- and RNA-based next-generation sequencing (NGS). While NGS is an efficient way to analyze multiple genes of interest at once, economic and technical factors may preclude its use in routine care globally, despite several guideline recommendations. The aim of this review is to present a summary of oncogenic gene fusions, with a focus on fusions that affect tyrosine kinase signaling, and to highlight the importance of testing for oncogenic fusions. We present an overview of the identification of oncogenic gene fusions and therapies approved for the treatment of cancers harboring gene fusions, and summarize data regarding treating fusion-positive cancers with no current targeted therapies and clinical studies of fusion-positive cancers. Although treatment options may be limited for patients with rare alterations, healthcare professionals should identify patients most likely to benefit from oncogenic gene fusion testing and initiate the appropriate targeted therapy to achieve optimal treatment outcomes.</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"119 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143827257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Overexpression of CIP2A is associated with poor prognosis in multiple myeloma","authors":"Xuewen Liu, Wei Cao, Shanshan Qin, Te Zhang, Junnian Zheng, Ying Dong, Pinghong Ming, Qian Cheng, Zheng Lu, Yang Guo, Baofu Zhang, Ying Liu","doi":"10.1038/s41392-025-02225-8","DOIUrl":"https://doi.org/10.1038/s41392-025-02225-8","url":null,"abstract":"<p>Correction to: <i>Signal Transduction and Targeted Therapy</i> https://doi.org/10.1038/sigtrans.2017.13, published online 26 May 2017</p>","PeriodicalId":21766,"journal":{"name":"Signal Transduction and Targeted Therapy","volume":"112 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}